【港股通】和黄医药：收到武田有关呋喹替尼在日本上市的里程碑付款

金吾资讯12:28

金吾财讯 | 和黄医药(00013)公告，继FRUZAQLA®（呋喹替尼）1毫克/5毫克胶囊在日本取得定价批准并由其合作伙伴武田（TSE：4502/NYSE：TAK）推出商业上市用于治疗经治的转移性结直肠癌患者后，和黄医药将收到一项里程碑付款。早前，FRUZAQLA®已取得日本厚生劳动省（MHLW）的生产及销售批准。FRUZAQLA®是日本超过十年来首个获批用于治疗转移性结直肠癌的口服创新靶向疗法...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2485404214?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2024-11-22 12:28","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2485404214","market":"hk","top_or_hot":-1,"title":"【港股通】和黄医药：收到武田有关呋喹替尼在日本上市的里程碑付款","media":"金吾资讯","content":"<div>\n<p>金吾财讯 | 和黄医药(00013)公告，继FRUZAQLA®（呋喹替尼）1毫克/5毫克胶囊在日本取得定价批准并由其合作伙伴武田（TSE：4502/NYSE：TAK）推出商业上市用于治疗经治的转移性结直肠癌患者后，和黄医药将收到一项里程碑付款。早前，FRUZAQLA®已取得日本厚生劳动省（MHLW）的生产及销售批准。FRUZAQLA®是日本超过十年来首个获批用于治疗转移性结直肠癌的口服创新靶向疗法...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241122122905abd65f4f&s=b\">网页链接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>【港股通】和黄医药：收到武田有关呋喹替尼在日本上市的里程碑付款</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n【港股通】和黄医药：收到武田有关呋喹替尼在日本上市的里程碑付款\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-11-22 12:28 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241122122905abd65f4f&s=b><strong>金吾资讯</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>金吾财讯 | 和黄医药(00013)公告，继FRUZAQLA®（呋喹替尼）1毫克/5毫克胶囊在日本取得定价批准并由其合作伙伴武田（TSE：4502/NYSE：TAK）推出商业上市用于治疗经治的转移性结直肠癌患者后，和黄医药将收到一项里程碑付款。早前，FRUZAQLA®已取得日本厚生劳动省（MHLW）的生产及销售批准。FRUZAQLA®是日本超过十年来首个获批用于治疗转移性结直肠癌的口服创新靶向疗法...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241122122905abd65f4f&s=b\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"HSCEI","symbol_name":"国企指数","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241122122905abd65f4f&s=b","article_id":"2485404214","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241122122905abd65f4f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2485404214","pubTimestamp":1732249721,"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"金吾财讯 | 和黄医药 公告，继FRUZAQLA1毫克/5毫克胶囊在日本取得定价批准并由其合作伙伴武田推出商业上市用于治疗经治的转移性结直肠癌患者后，和黄医药将收到一项里程碑付款。FRUZAQLA是日本超过十年来首个获批用于治疗转移性结直肠癌的口服创新靶向疗法，无论患者的生物标志物状态如何。FRUZAQLA获批用于治疗无法彻底治愈及无法切除，且化疗后病情进展的晚期或复发性结直肠癌。","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"HSCEI":"国企指数","BK1588":"回港中概股","HSTECH":"恒生科技指数","BK1587":"次新股","00013":"和黄医药","BK1191":"制药"},"translate_title":"[Hong Kong Stock Connect] Chi-Med: Received milestone payment from Takeda for the listing of fruquintinib in Japan","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"00013":1,"HSCEI":1,"HSTECH":1},"content_text":"金吾财讯 | 和黄医药(00013)公告，继FRUZAQLA®（呋喹替尼）1毫克/5毫克胶囊在日本取得定价批准并由其合作伙伴武田（TSE：4502/NYSE：TAK）推出商业上市用于治疗经治的转移性结直肠癌患者后，和黄医药将收到一项里程碑付款。早前，FRUZAQLA®已取得日本厚生劳动省（MHLW）的生产及销售批准。FRUZAQLA®是日本超过十年来首个获批用于治疗转移性结直肠癌的口服创新靶向疗法，无论患者的生物标志物状态如何。FRUZAQLA®获批用于治疗无法彻底治愈及无法切除，且化疗后病情进展的晚期或复发性结直肠癌。根据日本国立癌症研究中心的统计数据，结直肠癌是日本最常见的癌症类型，估计2023年有16.1万例新增病例，并造成5.4万人死亡。","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.29.2","shortVersion":"4.29.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2485404214"}